Effects of Gut Peptides on Bone Remodeling

Investigation of GLP-2 Mechanism of Action

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03574064

Acronym

KS-3

Enrollment

Registered

2018-06-29

Start date

2018-06-01

Completion date

2019-01-01

Last updated

2021-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

We will investigate effects of gut hormones on bone remodeling.

Interventions

OTHERGlucagon-Like Peptide-2 (GLP-2)

Glucagon-Like Peptide-2 (GLP-2) injection.

OTHERGlucose-dependent insulinotropic polypeptide (GIP)

Glucose-dependent insulinotropic polypeptide (GIP) injection.

OTHERGLP-2+GIP

GLP-2+GIP injection.

OTHERPlacebo

Placebo injection.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

50 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

Women Age above 50 years Postmenopausal Caucasian BMI 18.5 to 28.0 kg/m2.

Exclusion criteria

Smoking Medication believed to influence study outcome Weight change more than 3 kg whitin the last 3 months Overweight surgery Intestinal surgery Hgb\<7,0 mmol/L Decreased renal function

Design outcomes

Primary

Measure	Time frame	Description
C-terminal telopeptide (CTX). At all time points and AUC(0-240 min).	-10 minutes to 600 minutes	CTX is a marker of bone resorption. Measured in serum.
N-terminal propeptide of type 1 procollagen (P1NP). At all time points and AUC(0-240 min).	-10 minutes to 600 minutes	P1NP is a marker of bone formation. Measured in serum.

Secondary

Measure	Time frame	Description
Sclerostin	-10 minutes to 600 minutes	Bone marker.
Calcium	-10 minutes to 600 minutes	Measured in serum within 5 days.
Glucose	-10 minutes to 600 minutes	Measured in serum.
Glucose-dependent insulinotropic polypeptide (GIP)	-10 minutes to 600 minutes	Total and intact GIP. Measured in plasma.
C-peptide	-10 minutes to 600 minutes	Measured in serum.
Glukagon-like peptide-1 (GLP-1)	-10 minutes to 600 minutes	Measured in plasma.
Glucagon	-10 minutes to 600 minutes	Measured in plasma.
Glukagon-like peptide-2 (GLP-2)	-10 minutes to 600 minutes	Intact GLP-2. Measured in plasma.
PP	-10 minutes to 600 minutes	Measured in plasma.
Insulin	-10 minutes to 600 minutes	Measured in serum.
PTH	-10 minutes to 600 minutes	Bone marker. Measured in serum.

Other

Measure	Time frame	Description
Blood pressure	-10 minutes to 60 minutes	Measured before blood sampling.
Heart rate	-10 minutes to 60 minutes	Measured before blood sampling.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026